Broadstreet Health Economics And Outcomes Research
Broadstreet Health Economics and Outcomes Research, commonly referred to as Broadstreet HEOR, is a leading firm headquartered in California, specialising in health economics, outcomes research, and real-world evidence generation. Founded in 2015, the company has rapidly established itself as a key player in the healthcare industry, providing innovative solutions that inform decision-making for pharmaceutical and biotechnology companies. Broadstreet HEOR offers a range of core services, including economic modelling, health technology assessments, and patient-reported outcomes analysis. Their unique approach combines advanced analytics with a deep understanding of healthcare systems, enabling clients to navigate complex market landscapes effectively. With a strong presence across major operational regions in North America and Europe, Broadstreet HEOR is recognised for its commitment to delivering high-quality, evidence-based insights that drive value in healthcare.
DitchCarbon Score
How does Broadstreet Health Economics And Outcomes Research's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Broadstreet Health Economics And Outcomes Research's score of 6 is lower than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Broadstreet Health Economics And Outcomes Research's reported carbon emissions
Broadstreet Health Economics and Outcomes Research, headquartered in Canada, has set ambitious climate commitments aimed at significantly reducing its carbon footprint. As of now, there is no available data on their absolute carbon emissions in kg CO2e. However, the company has established clear reduction targets approved by the Science Based Targets initiative (SBTi). Broadstreet commits to maintaining zero Scope 1 and Scope 2 emissions through 2030, using 2022 as the base year. This commitment reflects an absolute reduction target of 100% for these scopes. Additionally, the company aims to measure and reduce its Scope 3 emissions, although specific targets for this category have not been detailed. These initiatives align with the industry's best practices for climate action, demonstrating Broadstreet's dedication to sustainability and its role in combating climate change. The targets are consistent with the necessary reductions to limit global warming to 1.5°C, showcasing the company's proactive approach to environmental responsibility.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Broadstreet Health Economics And Outcomes Research is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
